First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial.

Lisa Paschold,Alexander Stein,Benjamin Thiele,Joseph Tintelnot,Svenja-Sibylla Henkes, Cornelia Coith,Christoph Schultheiß,Klaus Pantel,Sabine Riethdorf,Mascha Binder

Journal for immunotherapy of cancer（2023）

引用 1|浏览12

暂无评分

摘要

Prospective validation of this liquid biomarker triad is needed to molecularly define HER2+ EGA patient subsets with different needs in the first-line systemic treatment setting.

查看译文

关键词

positive esophagogastric adenocarcinoma,liquid biomarker analysis,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要